Plasma phosphorylated α-synuclein relates to cognitive impairment in patients with Parkinson’s disease
Objective: To investigate whether plasma phosphorylated α-synuclein (p-syn) were associated with cognitive function in Parkinson’s disease (PD). Background: Parkinson’s disease (PD) is the second most…The Prodromal PD study – multiple biomarkers for early diagnosis?
Objective: The study aims to deepen our understanding of the prodromal phase of Parkinson’s disease (PD) Background: At the time of PD diagnosis, nigrostriatal degeneration…Prasinezumab reduced progression of Parkinson’s disease motor features measured by Roche PD Mobile Application v2 sensor features: PASADENA Phase II Part 1
Objective: To determine whether digital biomarker sensor data detect slowing in progression of core motor features of Parkinson’s disease (PD) in individuals with early PD…Dissociable contribution of serum NfL and p-tau181 to cognitive impairment and mild cognitive impairment in Parkinson’s disease.
Objective: To analyze the contribution of serum NfL and p-tau181 levels to cognitive impairment and mild cognitive impairment (PD-MCI) in non-demented PD patients. Background: Autopsy…GBA Mutation Accumulates Higher Alpha-Synuclein in Alpha-Synucleinopathies
Objective: To investigate whether post-translational modifications of α-synuclein will give rise to species that differ between PD cases with N370S GBA mutation and WT-PD. Background:…Quantitative systems pharmacology modelling of Parkinson’s disease to compare anti-α-synuclein therapeutics
Objective: We previously constructed a quantitative systems pharmacology (QSP) model of Parkinson’s disease (PD) that combines pathogenesis and spatial propagation of misfolded α-synuclein (Asyn) [1].…A new alpha-synuclein missense variant (Thr72Met) in two Turkish families with Parkinson’s disease
Objective: To report the identification of a novel variant in the gene encoding alpha-synuclein (SNCA), segregating with Parkinson’s Disease (PD) in two families of Turkish…The mitochondrial targeted drug SBT-272 attenuates dopaminergic neuron loss, alpha-synuclein burden and neuroinflammation in a mouse model of Parkinson’s Disease
Objective: To assess the preclinical efficacy of the investigational drug SBT-272 in a mouse model of Parkinson’s Disease (PD). Background: SBT-272 is a peptidomimetic drug…Methylation status of SNCA gene in multiple system atrophy and Parkinson’s disease
Objective: Parkinson’s disease (PD) and multiple system atrophy (MSA) are classical synucleinopathies caused by misfolding of alpha-synuclein protein. Clinical picture of PD and MSA in…Validation of the Neuroprotective Potential of SLP-2 against alpha-synuclein neuropathology in a Mouse Model of Parkinson’s Disease
Objective: We aim to validate the neuroprotective potential of SLP-2 against α-syn neuropathology and neurodegeneration of dopaminergic neurons in a mouse model of Parkinson’s disease.…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 51
- Next Page »